Skip to main content

$11.22 -0.22 (-1.92%)

High

$11.49

Low

$11.20

Trades

4,718

Turnover

$7,499,551

Volume

664,557
30 June 2023 at 4:12pm
Register to track TLX and receive email alerts.
Subject
TLX Ann: ZIRCON Phase 3 Imaging Study Completes Targets Enrolment

TLX Ann: Cancellation of Share Purchase Plan

TLX Ann: FY21 Corporate Governance Statement - replacement

TLX Ann: Appendix 4G - Key to Governance Disclosures - replacement

TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act

TLX Ann: Application for quotation of securities - TLX

TLX Ann: 2021 Full Year Results Presentation

TLX Ann: Annual Report for the year ended 31 December 2021

TLX Ann: Corporate Governance Statement

TLX Ann: Appendix 4G - Key to Governance Disclosures

TLX Ann: Appendix 4E - Results for announcement to the market

TLX Ann: Commercial Distribution Agreement for Illuccix for Australia

TLX Ann: Ceasing to be a substantial holder

TLX Ann: Update - Proposed issue of securities - TLX

TLX Ann: Share Purchase Plan extended to Friday 25 February 2022

TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act 2001

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Telix Granted Illuccix EU Regulatory Review Extension

TLX Ann: ZSP:Sydney Airport to be removed from the S&P/ASX 200 Index

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Notice of change of interests of substantial holder

TLX Ann: Appendix 3Y - C Behrenbruch - exercise of options

TLX Ann: Telix Full Year Results and Investor Conference Call details

TLX Ann: Despatch of SPP Booklet to Eligible Shareholders

TLX Ann: App 3Y Change of Directors Interest Notice - A Kluge

TLX Ann: Notice of change of interests of substantial holder

TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act 2001

TLX Ann: Notice of change of interests of substantial holder

TLX Ann: Application for quotation of securities - TLX

TLX Ann: App 3Y Change of Directors Interest Notice - C Behrenbruch

TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act 2001

TLX Ann: Application for quotation of securities - TLX

TLX Ann: 1st Patient Dosed ProstACT Prostate Cancer Therapy Program

TLX Article: M&A boom reshaping the ASX one deal at a time

TLX Ann: Proposed issue of securities - TLX

TLX Ann: Appendix 4C and Activities Report for December 2021 Quarter

TLX Ann: Capital Raise Presentation

TLX Ann: Telix completes $175M placement and launches $25M SPP

TLX Article: Telix Pharma bulking up with $200m raising

TLX Ann: Trading Halt

TLX Ann: Investor Presentation to JP Morgan Healthcare Conference

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Targeted Alpha Therapy for Bladder Cancer 1st patient dosed

TLX Ann: FDA Approves Telix Prostate Cancer Imaging Product Illuccix

TLX Ann: Illuccix EU Regulatory Submission Progress Update

TLX Ann: NUCLIBER - Distribution Agreement for Illuccix in Spain

TLX Ann: Illuccix Granted Use Authorisation in Brazil

TLX Ann: Investor Presentation - November 2021

TLX Ann: Australian TGA Approves Illuccix for Prostate Cancer Imaging

TLX Ann: Activities Report and App 4C - September 2021 quarter

Register to track TLX and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC